Valuation multiples - P/BV, P/E

Dear community,

I am a self-taught person, and I seek your guidance.

What is the rationale for using the P/E ratio to value companies operating within healthcare?

While I do understand why we use it for financial institutions that rely heavily on interest income, I do not see the rationale behind using it for healthcare companies.

Also: why do we use P/BV or P/TBV for banks? I found that "Book value per share is a good measure to value bank stocks. In this scenario, the so-called price-to-book (P/B) ratio is applied with a bank's stock price compared to equity book value per share. The alternative of comparing a stock's price to earnings, or price-to-earnings (P/E) ratio, may produce unreliable valuation results, as bank earnings can easily swing back and forth in large variations from one quarter to the next," and I quite don't get it.

Could someone explain it?

Thanks!

3 Comments
 

Hi Blendzior321, any of these threads helpful:

I hope those threads give you a bit more insight.

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 
Most Helpful
"Blendzior321" Dear community,

I am a self-taught person, and I seek your guidance.

What is the rationale for using the P/E ratio to value companies operating within healthcare?

While I do understand why we use it for financial institutions that rely heavily on interest income, I do not see the rationale behind using it for healthcare companies.

Also: why do we use P/BV or P/TBV for banks? I found that "Book value per share is a good measure to value bank stocks. In this scenario, the so-called price-to-book (P/B) ratio is applied with a bank's stock price compared to equity book value per share. The alternative of comparing a stock's price to earnings, or price-to-earnings (P/E) ratio, may produce unreliable valuation results, as bank earnings can easily swing back and forth in large variations from one quarter to the next," and I quite don't get it.

Could someone explain it?

Thanks!

Good on you for being self-taught. Let me try to help.

1) P/E actually doesn't make too much sense for financial institutions because of leverage. It is best used for stable companies with reliable cash flow, leverage, growth, and risk that allows it to be compared to similarly stable companies. To see why, consider a standard one period DCF in per share terms:

P = FCF/(r-g) - ND

If you divide both sides by earnings

P/E = (FCF/E)/(r-g) - ND/E

So if you use P/E you are making implicit assumptions about these four items in perpetuity. Big pharma is typically stable across all of them, so its a pretty good metric.

2) P/B is typically a bullshit metric because BV doesn't actually mean anything. It's just a plug variable accountants invented to make the balance sheet balance. Since assets are valued at cost, it tells you nothing about how the company is performing now.

The exception is banks and real estate, where accounting rules have them mark BV to market. In ths case, BV is a good idea of the net value of assets the company is holding. And P/B is a measure of premium of the company over the assets it has, i.e. you believe it can squeeze even more returns out of its assets as compared to if it liquidated everything.

 

Aut architecto sint non molestias id. Blanditiis eius blanditiis amet blanditiis aut exercitationem. Provident non inventore consequuntur repudiandae rerum doloremque id ut. Aut qui in tempore et quidem qui ut. Nesciunt nihil ut ut voluptas dolor et accusantium.

Modi minima animi nobis. Voluptas est et eos officiis veniam aut. Qui quis dolores maxime officia. Ut ullam earum adipisci sunt qui aliquid ea. Modi accusamus neque dolorem animi illo accusantium officia. Blanditiis a dicta distinctio sit. Error iusto distinctio excepturi sapiente.

Quisquam quia velit eligendi ad earum nulla. In assumenda est voluptatem veritatis at. Nulla aperiam sed dolor vel sed alias beatae.

Aut distinctio vel placeat quis quam harum ex eos. Dolorem deserunt consectetur vel. Voluptatum ratione officia labore sed aut.

"He was an idiot! He was a bouncer who got his Series 7" - Josh Brown

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”